CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 161 enrolled
Drug / intervention
TAK-981 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04381650
NCT04381650Phase 2Completed
CompareCT.gov

A Phase 1b/2 Study of TAK-981 Plus Pembrolizumab to Evaluate the Safety, Tolerability, and Antitumor Activity of the Combination in Patients With Select Advanced or Metastatic Solid Tumors

Takeda·interventional·Posted May 11, 2020·Updated Dec 10, 2025

In Brief

A Phase 2 clinical trial evaluating TAK-981 and Pembrolizumab for Advanced or Metastatic Solid Tumors. Completed, enrolled 161 participants across 52 sites in 9 countries.

Detailed Summary

TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors. The study aims are to evaluate the safety, tolerability, and preliminary efficacy of TAK-981 in combination with pembrolizumab. Participants will be on this combination treatment for 21-day cycles. They will continue with this treatment for up to 24 months or until participants meet any discontinuation criteria.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Metastatic Solid Tumors
CountriesBrazil, China, Croatia, Japan, Latvia, Lithuania, Poland, Switzerland, United States
CollaboratorsTakeda Development Center Americas, Inc.

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 11, 2020
Enrollment StartAug 17, 2020
Primary CompletionOct 29, 2024
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 6.1 years ago

Interventions

TAK-981drug

TAK-981 IV infusion.

Pembrolizumabdrug

Pembrolizumab IV infusion.